These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 11838623

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder.
    Carvalhal AS, de Abreu PB, Spode A, Correa J, Kapczinski F.
    J Clin Psychiatry; 2003 Apr; 64(4):421-4. PubMed ID: 12716244
    [Abstract] [Full Text] [Related]

  • 25. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
    Carter CS, Fawcett J, Hertzman M, Papp LA, Jones W, Patterson WM, Swinson RP, Weise CC, Maddock RJ, Denahan AQ.
    J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
    [Abstract] [Full Text] [Related]

  • 26. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
    Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M.
    Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Predicting response: noradrenaline reuptake inhibition.
    Montgomery SA.
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 1():S21-6. PubMed ID: 10468325
    [Abstract] [Full Text] [Related]

  • 29. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group.
    Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD.
    Am J Psychiatry; 1998 Nov; 155(11):1570-7. PubMed ID: 9812120
    [Abstract] [Full Text] [Related]

  • 30. An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder.
    Tehrani-Doost M, Moallemi S, Shahrivar Z.
    J Child Adolesc Psychopharmacol; 2008 Apr; 18(2):179-84. PubMed ID: 18439114
    [Abstract] [Full Text] [Related]

  • 31. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.
    Scates AC, Doraiswamy PM.
    Ann Pharmacother; 2000 Nov; 34(11):1302-12. PubMed ID: 11098346
    [Abstract] [Full Text] [Related]

  • 32. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.
    Bakker A, van Dyck R, Spinhoven P, van Balkom AJ.
    J Clin Psychiatry; 1999 Dec; 60(12):831-8. PubMed ID: 10665629
    [Abstract] [Full Text] [Related]

  • 33. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.
    Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjödin I, Penttinen JT, Pedersen T, Lehto HJ.
    J Clin Psychiatry; 1998 Oct; 59(10):528-34. PubMed ID: 9818634
    [Abstract] [Full Text] [Related]

  • 34. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
    Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R.
    Arch Gen Psychiatry; 1998 Nov; 55(11):1010-6. PubMed ID: 9819070
    [Abstract] [Full Text] [Related]

  • 35. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
    Ferguson JM, Mendels J, Schwart GE.
    Int Clin Psychopharmacol; 2002 Mar; 17(2):45-51. PubMed ID: 11890185
    [Abstract] [Full Text] [Related]

  • 36. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A, Bosc M, Polin V.
    J Psychopharmacol; 1997 Mar; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [Abstract] [Full Text] [Related]

  • 37. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
    Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A.
    Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
    [Abstract] [Full Text] [Related]

  • 38. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
    Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I.
    Psychopharmacology (Berl); 2007 Jun; 192(3):441-8. PubMed ID: 17310385
    [Abstract] [Full Text] [Related]

  • 39. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.
    Hajós M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH.
    CNS Drug Rev; 2004 Jun; 10(1):23-44. PubMed ID: 14978512
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B.
    Clin Neuropharmacol; 2009 Jun; 32(4):179-82. PubMed ID: 19644227
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.